Abstract
Introduction
As the incidence of cancer is increasing, cancer management has become a team effort consisting of family members, physicians, surgeons, radiations and medical oncologists, psychiatrists and physiotherapists.
The objective of this team is to provide a cure or palliation with minimal side effects and quality of life to the patient.
Radiation therapy has become target-orientated to avoid injury to normal tissue but now chemoradiation is the preferred modality. In spite of giving promising results, these anticancer drugs have a number of side effects, which include toxic effects on bone marrow, kidney, lymphoreticular tissue, mucosa and cochlea 1 . In India, the oncology department is overloaded with cancer patients; hence, anticancer drugs are being infused in the parent departments by nurses and residents. However, extravasational toxicity is one of the dreaded complications of anticancer drugs, which didnot find a place in the majority of clinical textbooks [1] [2] [3] [4] [5] [6] [7] other than oncology, and hence many of the residents may be unaware of this preventable catastrophe 8 . The incidence of extravasations in adults is 0.1% to 6.5% 9, 10 . Extravasation can occur in any centre and even in highly advanced oncology centres 11 , but these advanced centres have specially trained oncology-nursing staff. Commonly, chemotherapy is infused in clinical or parental departments of the patient, and work of infusion is left to a house surgeon or an intern, who may not have yet acquired a reasonable experience in venepuncture. Even the resident may not have adequate knowledge of the measures to be undertaken in case of extravasation due to absence of this complication and its management in the majority of clinical textbooks.
The objective of this paper is to review and present the clinical features and management of extravasation of these anticancer drugs so that the first line staff (residents/nurses) gets acquainted to this complication and its management. 
Classification based on mode of tissue injury

Guidelines for infusion of cytotoxic drugs
Institutional policy
There are specific guidelines for infusion of anticancer drugs 15, [17] [18] [19] [20] [21] , but the institutes or hospitals should also have their own policy on chemotherapy infusion. The attending physician and nursing staff should be familiar with the anticancer drug and its complication. The infusion should be given at the time of maximum staff strength and care. The ward should have information charts displayed both for staff and patient 22 . All the antidote drugs should be at the bedside of the patient. Patient should be informed about the symptoms of extravasation and its complications, and explained that despite best efforts, extravasation can occur 22 . All extravasation incidences should be brought to the notice of the department and institutional oncology board. They can review the case and decide on further management of the patient and preventive measures.
Intravenous access
This is the most important step in the prevention of extravasation. First of all, assess the general condition and age of the patient. Patient with paralysis, sensory deficit, tracheostomy or impaired higher mental function needs extra care due to inability to alert the staff during extravasation 23 . Elderly patients have increased risk of extravasation due to fragile veins. Similar risk is involved with deep veins, previous infusion within 48 h, multiple attempts for venous access, radiation or regional lymph node clearance of the limb 15, 22 . The second most important step is to decide on central or peripheral intravenous access. Commonly, peripheral intravenous access is preferred. However, drugs to be given longer than 1 h should be administered only via a central line 15, 23, 24 . The flexible intracatheter devices should be used, as other rigid devices have a tendency for vessel injury 8, 15 . Forearm is the preferred site due to catheter stability and muscle protection for the nerve and tendons in the event of extravasation, which is inevitable in case of access on hand or wrist 8 . Venous access should be secured in a single attempt and in case of failure, the site should be changed to another proximal vein. The device should be covered with transparent dressing so that the signs of extravasation are visible to the patient and staff. Intravenous access should be checked by running normal saline intravenously. This step immediately confirms extravasation and also hydrates the patient, a prerequisite for chemotherapy. Now, anticancer drugs are started, and the patient is instructed to alert the attending staff if there is any pain, itching, stoppage of infusion or oedema in the limb.
Clinical features of extravasation
Extravasation of cytotoxic drugs leads to stoppage of infusion, and the patient will complain of excruciating pain and itching in the infusion site. Within a few hours, the extravasation area will show erythema, oedema and induration. Without intervention, these sign and symptoms will increase, and skin will show discolouration and desquamation of epidermis or blister formation in a few days. Extravasation of a large dose of cytotoxic drug leads to ischaemia and ulcer formation (Figure 1 ).
Management of extravasation
• Immediate bedside management: Immediate management of extravasation reduces the tissue injury, and morbidity is inevitable if this step is delayed. On extravasation, infusion of drug should be stopped at once and normal saline infusion should be started. In case of an irritant drug, intravenous cannula should be removed while it is left in place in case of vesicant drug and proper antidote should be given 15 . The limb is elevated, and cold pack is applied to the local site. Hot packs are applied in extravasation of vinca alkaloids, as it causes vasodilatation and diffusion of the drug from the site. Parenteral strong analgesic helps in the reduction of inflammatory reaction and its symptoms.
• Use specific antidotes: There are a number of studies and case reports in literature 9,10,18,25-45 to show 
a) Dimethylesulfoxide (DMSO):
This drug is applied topically in case of extravasation of anthracyclines and mitomycin C. 1-2 ml of 1 mM 50%-99% DMSO is applied to the effective area thrice a day for 1-2 weeks. Oliver et al. 25 used topical DMSO every 6 h for 14 days in 20 patients with extravasation of anthracycline and in a follow-up of 16 patients for 3 months; no patient developed skin ulceration or necrosis. Bertelli et al. 27 used 99% DMSO topically every 8 h for 7 days in 127 patients with various vesicant drugs, and only one patient had skin ulceration. b) Hyaluronidase: This drug breaks hyaluronic acid and increases the permeability of connective tissue and hence the diffusion of extravasated drug 10, 15, 24 . It is recommended in vinca alkaloids, epipodophylotoxin and taxanes 26, 31 extravasations. It is injected through the existing cannula or subcutaneously in a clockwise manner if cannula has been removed. About 1-6 ml of 150 U/ ml hyaluronidase is sufficient, but its dose corresponds to the amount of extravasated drug.
It is contraindicated in case of infection and cancerous infiltration of the site, as it can ease the spread of disease. c) Dexrazoxane: It is a recent FDA-approved antidote for anthracycline extravasation. Exact mechanism of action is unknown but some evidences suggest reversible topoisomerase II inhibition and binding to iron, which prevents the formation of free radicals responsible for tissue injury 22, 32 . It is infused slowly over 1-2 h in a large vein other than the injured vein in a dose of 1 gm m -2 within 6 h of extravasation, and repeated again on the second day with the same dose and 500 mg m -2 on the third day. Based on anecdotal reports, DMSO interacts with dexrazoxane and decreases its efficacy; therefore, concurrent use should be avoided 32 . , and E , heparin fraction 41 , melatonin
42
, hyperbaric oxygen 43 . Scuderi et al. 44 have reported local injection of saline (20-90 ml) with occlusive topical application of corticosteroid to avoid skin necrosis. Local infiltration of hydrocortisone in anthracycline extravasation did not prevent skin necrosis in mice model 45 .
• Surgical intervention: Surgical intervention is reserved in cases that have not received antidote or presented late with erythema or necrosis. In two studies 46, 47 , saline washout with liposuction prevented skin necrosis, performed within 24 h of various extravasation injuries. This procedure is performed by irrigating the subcutaneous tissue with normal saline through a 4-mm blunt tipped liposuction cannula, and removing subcutaneous tissue with the extravasated drug.
Untreated extravasation leads to skin necrosis and needs plastic surgeon intervention. Surgical intervention involves two approaches [48] [49] [50] [51] [52] [53] [54] [55] . One approach involves extensive surgical debridement preferably under fluorescence microscope within 24 h to 1 week after extravasation and secondary wound closure. The second conservative approach involves daily saline dressing. The wound is then covered with split skin graft or flap. Necrosis of peripheral vessels and nerves of limb may need amputation. However, immediate intervention is indicated in case of non-resolving erythema, pain or swelling and presence of large skin defects. Few experimental animal and human studies have reported good results with the use of granulocyte macrophage colony stimulating factor (GM-CSF) in the management of ulcers in anthracycline extravasation 19, [56] [57] [58] [59] .
• Physiotherapy: It is indicated in late complications (functional or neural loss of the limb), but is rare.
Conclusion
Extravasation is a dreaded complication of anticancer drugs and can be avoided through proper guidelines. Once extravasation occurs, tissue injury is inevitable but can be reduced with the proper antidote. All anticancer drugs should be infused by trained staff, and preferably in the oncology department only. The clinical textbooks should cite this complication and its management, so that primary clinical physicians are able to handle this complication in its golden hour.
